Propranolol absorption in untreated coeliac disease

Area of Science:

• Gastroenterology
• Pharmacokinetics
• Internal Medicine

Background:

• Coeliac disease is an autoimmune disorder affecting the small intestine.
• Malabsorption is a common complication of untreated coeliac disease.
• The impact of coeliac disease on the absorption of specific medications like propranolol is not fully understood.

Purpose of the Study:

• To investigate the effect of untreated coeliac disease on the bioavailability and elimination of propranolol.
• To determine if propranolol absorption is impaired in the proximal jejunum of coeliac patients.

Main Methods:

• Plasma concentrations of propranolol were measured after oral and intravenous administration in coeliac patients and healthy controls.
• A perfusion technique was employed to assess propranolol absorption in the proximal jejunum.

Main Results:

• Bioavailability and clearance of propranolol were similar between coeliac patients and normal subjects.
• Propranolol absorption in the proximal jejunum was significantly reduced (71%) in untreated coeliac patients compared to controls.
• Overall small bowel absorption of propranolol was not impaired.

Conclusions:

• Untreated coeliac disease leads to decreased propranolol absorption specifically in the proximal jejunum.
• Despite localized absorption defects, overall propranolol bioavailability and elimination are not significantly altered in coeliac patients.
• These findings suggest compensatory mechanisms or absorption in other parts of the small bowel may maintain overall drug levels.